CY1116894T1 - Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων - Google Patents

Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων

Info

Publication number
CY1116894T1
CY1116894T1 CY20151100997T CY151100997T CY1116894T1 CY 1116894 T1 CY1116894 T1 CY 1116894T1 CY 20151100997 T CY20151100997 T CY 20151100997T CY 151100997 T CY151100997 T CY 151100997T CY 1116894 T1 CY1116894 T1 CY 1116894T1
Authority
CY
Cyprus
Prior art keywords
pal
compositions
methods
fenylalanine
lysis
Prior art date
Application number
CY20151100997T
Other languages
English (en)
Inventor
Michel C Vellard
Paul A Fitzpatrick
Emil D Kakkis
Daniel J Wendt
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116894(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of CY1116894T1 publication Critical patent/CY1116894T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αφορά αμμωνιακή λυάση φαινυλαλανίνης (PAL) που παράγεται από προκαρυωτικά, όπου τέτοια προκαρυωτική PAL όπου η παραλλαγή PAL έχει μεγαλύτερη δραστικότητα μετατροπής φαινυλαλανίνης και/ή μειωμένη ανοσογονικότητα συγκριτικά με PAL φυσικού τύπου. Η εφεύρεση παρέχει έτσι συνθέσεις βακτηριακής PAL και βιολογικά δραστικά θραύσματα, μεταλλάγματα, παραλλαγές και ανάλογα αυτής, όπως επίσης και μεθόδους για την παραγωγή, καθαρισμό, και χρήση τέτοιων συνθέσεων για θεραπευτικούς και βιομηχανικούς σκοπούς.
CY20151100997T 2007-05-25 2015-11-06 Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων CY1116894T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
EP08754717.0A EP2152868B1 (en) 2007-05-25 2008-05-23 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

Publications (1)

Publication Number Publication Date
CY1116894T1 true CY1116894T1 (el) 2017-04-05

Family

ID=39868905

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100997T CY1116894T1 (el) 2007-05-25 2015-11-06 Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων
CY2019039C CY2019039I2 (el) 2007-05-25 2019-10-17 Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2019039C CY2019039I2 (el) 2007-05-25 2019-10-17 Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων

Country Status (30)

Country Link
US (1) US7534595B2 (el)
EP (2) EP2152868B1 (el)
JP (1) JP5670183B2 (el)
KR (2) KR20150038753A (el)
CN (1) CN101842482B (el)
AR (2) AR066716A1 (el)
AU (1) AU2008263190B2 (el)
BR (1) BRPI0811267B8 (el)
CA (1) CA2687450C (el)
CL (1) CL2008001497A1 (el)
CY (2) CY1116894T1 (el)
DK (1) DK2152868T3 (el)
EA (1) EA018443B1 (el)
ES (1) ES2551315T3 (el)
HK (1) HK1135141A1 (el)
HR (1) HRP20151268T1 (el)
HU (2) HUE025784T2 (el)
IL (1) IL202132A (el)
LT (1) LTC2152868I2 (el)
LU (1) LUC00133I2 (el)
MX (1) MX2009012453A (el)
MY (1) MY151413A (el)
NL (1) NL301011I2 (el)
NO (1) NO2019037I1 (el)
PE (1) PE20090315A1 (el)
PL (1) PL2152868T3 (el)
PT (1) PT2152868E (el)
SI (1) SI2152868T1 (el)
TW (1) TWI418633B (el)
WO (1) WO2008153776A1 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
SI3025728T1 (sl) * 2010-02-04 2018-11-30 Biomarin Pharmaceutical Inc. Metoda za čiščenje prokariontskih fenilalanin amonij-liaznih variant
US20150246083A1 (en) * 2012-07-27 2015-09-03 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
ES2729048T3 (es) * 2013-04-18 2019-10-30 Codexis Inc Polipéptidos de fenilalanina amoníaco-liasa modificados
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
AU2015241422B2 (en) 2014-04-01 2020-12-03 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
HUE056444T2 (hu) 2014-04-16 2022-02-28 Codexis Inc Génmódosított tirozin-ammónia-liáz
HUE062016T2 (hu) 2014-12-22 2023-09-28 Codexis Inc Humán alfa-galaktozidáz variánsok
TW202330904A (zh) * 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
IL305149A (en) 2016-07-26 2023-10-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
JP7024951B2 (ja) * 2016-08-30 2022-02-24 三菱ケミカル株式会社 変異型酵素の製造方法及び変異型アルコールアシルトランスフェラーゼ
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
EP3579867A4 (en) * 2017-02-13 2021-03-10 Codexis, Inc. MANIPULATED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
CN113164762A (zh) 2018-05-09 2021-07-23 生物马林药物股份有限公司 苯丙酮尿症的治疗方法
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
WO2019241132A1 (en) 2018-06-12 2019-12-19 Codexis, Inc. Engineered tyrosine ammonia lyase
CN112672989A (zh) * 2018-07-12 2021-04-16 科德克希思公司 工程化苯丙氨酸氨裂合酶多肽
SG11202105668PA (en) 2018-12-14 2021-06-29 Codexis Inc Engineered tyrosine ammonia lyase
CA3123598A1 (en) 2018-12-20 2020-06-25 Codexis, Inc. Human alpha-galactosidase variants
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
MX2022002473A (es) 2019-08-30 2022-08-02 Codexis Inc Variantes de lipasa modificadas geneticamente.
BR112022011760A2 (pt) 2019-12-20 2022-08-30 Codexis Inc Fragmento de alfa glicosidase ácida recombinante e/ou de alfa glicosidase ácida recombinante biologicamente ativa, alfa glicosidase ácida recombinante, composição, sequência polinucleotídica recombinante, vetor de expressão, vetor de expressão pdh, célula hospedeira, método para produzir uma variante de alfa glicosidase ácida recombinante, variante de alfa glicosidase ácida recombinante, composição farmacêutica para o tratamento da doença de pompe, composição farmacêutica, método para tratar e/ou prevenir os sintomas da doença de pompe em um indivíduo, e, uso das composições
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用ａａｖ及治療調配物之苯酮尿症治療
BR112023003643A2 (pt) 2020-08-28 2023-03-28 Codexis Inc Amilase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma amilase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, composição farmacêutica para o tratamento de insuficiência pancreática, e, uso
WO2022047262A1 (en) 2020-08-28 2022-03-03 Codexis, Inc. Engineered protease variants
JP2024519847A (ja) * 2021-05-19 2024-05-21 ビオマリン プハルマセウトイカル インコーポレイテッド 原核生物フェニルアラニンアンモニアリアーゼの組成物及び青年対象を治療する方法
WO2023044381A1 (en) * 2021-09-16 2023-03-23 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) * 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) * 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
EP1287830B1 (en) * 1992-11-19 2009-08-26 Anticancer, Inc. Use of methioninase as an antitumor agent in anti-methionine chemotherapy
EP0692029B1 (en) * 1992-12-04 2007-05-09 Me Medical Enzymes Ag Genetically engineered glutaminase and its use in therapy
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
DK75593D0 (el) * 1993-06-25 1993-06-25 Novo Nordisk As
WO1995024928A2 (en) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) * 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
CA2315944A1 (en) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) * 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) * 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
WO2000047236A1 (en) * 1999-02-12 2000-08-17 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
AU783208B2 (en) * 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) * 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
CN1461344A (zh) * 2000-07-25 2003-12-10 免疫医疗公司 多价靶结合蛋白
US6897357B2 (en) * 2000-09-26 2005-05-24 Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (PAL) gene in wounded lettuce tissue
JP4344136B2 (ja) * 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
AU2003216403A1 (en) 2002-02-26 2003-09-09 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
CN1668637B (zh) * 2002-07-17 2010-05-26 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
CA2506026A1 (en) 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)
AU2004247737B2 (en) * 2003-06-11 2009-04-23 Wyeth Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP2008513027A (ja) 2004-09-17 2008-05-01 バイオマリン ファーマシューティカル インコーポレイテッド フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体
US20090038023A1 (en) * 2005-03-10 2009-02-05 Verenium Corporation Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Also Published As

Publication number Publication date
KR101603796B1 (ko) 2016-03-17
TW200902052A (en) 2009-01-16
HRP20151268T1 (hr) 2015-12-18
NL301011I2 (nl) 2020-05-13
CN101842482A (zh) 2010-09-22
WO2008153776A8 (en) 2009-07-30
AR066716A1 (es) 2009-09-09
BRPI0811267B1 (pt) 2020-11-10
PE20090315A1 (es) 2009-03-19
SI2152868T1 (sl) 2015-12-31
MX2009012453A (es) 2010-01-25
NO2019037I1 (no) 2019-10-16
CY2019039I1 (el) 2020-05-29
EA018443B1 (ru) 2013-08-30
US20080008695A1 (en) 2008-01-10
IL202132A0 (en) 2010-06-16
EP2152868A1 (en) 2010-02-17
PT2152868E (pt) 2015-11-13
HUE025784T2 (en) 2016-05-30
EP2152868B1 (en) 2015-09-02
AU2008263190A1 (en) 2008-12-18
AU2008263190B2 (en) 2014-04-17
DK2152868T3 (en) 2015-11-16
CY2019039I2 (el) 2020-05-29
LUC00133I2 (el) 2020-07-16
AR110834A2 (es) 2019-05-08
LUC00133I1 (el) 2019-10-16
JP5670183B2 (ja) 2015-02-18
LTC2152868I2 (lt) 2020-09-25
WO2008153776A1 (en) 2008-12-18
LTPA2019517I1 (lt) 2019-10-25
HUS1900049I1 (hu) 2019-11-28
MY151413A (en) 2014-05-30
BRPI0811267B8 (pt) 2021-05-25
CL2008001497A1 (es) 2009-01-09
HK1135141A1 (zh) 2010-05-28
PL2152868T3 (pl) 2016-01-29
KR20150038753A (ko) 2015-04-08
BRPI0811267A2 (pt) 2014-10-07
CA2687450A1 (en) 2008-12-18
TWI418633B (zh) 2013-12-11
CN101842482B (zh) 2014-10-22
JP2010529835A (ja) 2010-09-02
EA200970980A1 (ru) 2010-04-30
CA2687450C (en) 2019-03-26
IL202132A (en) 2017-06-29
KR20100024437A (ko) 2010-03-05
NL301011I1 (nl) 2019-10-16
EP2657335A1 (en) 2013-10-30
US7534595B2 (en) 2009-05-19
ES2551315T3 (es) 2015-11-18

Similar Documents

Publication Publication Date Title
CY1116894T1 (el) Συνθεσεις προκαρυωτικης αμμωνiακης λυασης φαινυλαλανινης και μεθοδοι χρησιμοποιησης αυτων των συνθεσεων
CY1118222T1 (el) Συνθεσεις λυασης φαινυλαλανινης αμμωνιας προκαρυωτικων και μεθοδοι αγωγης καρκινου χρησιμοποιωντας συνθεσεις εξ' αυτης
CA2782444C (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
DK2046820T3 (da) Muteiner af tåre-lipocalin og fremgangsmåder til opnåelse deraf
CY1118048T1 (el) Αντι-ιικες ενωσεις
EA201490132A1 (ru) Противовирусные соединения
MX2008008152A (es) Compuestos heterociclicos biciclicos.
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
MX2010009646A (es) Agentes terapeuticos antivirales.
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
TW200722079A (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EA201171481A1 (ru) Способ получения высококонцентрированного препарата иммуноглобулина для подкожного применения
EA200971074A1 (ru) Антивирусные соединения
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201001639A1 (ru) Композиции и способы их получения и применения
CY1114883T1 (el) Καινοφανεις αντιβακτηριακοι παραγοντες για την αγωγη των κατα gram θετικων λοιμωξεων
NZ706052A (en) Romidepsin solid forms and uses thereof
MX2011010451A (es) Derivados de oxadiazol.
TW200640886A (en) Crystalline forms of linezolid intermediate
EA200800570A1 (ru) Фосфонированные рифамицины и их применение для профилактики и лечения костных и суставных инфекций
MX2009000768A (es) Lactamas macrociclicas.
MX2009009074A (es) Macrolidos basados en eritromicina.
HU0402466D0 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process